Trials / Completed
CompletedNCT02536586
A Study of LY3023414 in Japanese Participants With Advanced Cancer
A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the tolerability of an investigational drug known as LY3023414 in Japanese participants with advanced cancer or cancer that has spread to another part(s) of the body. The study will also explore the safety of the drug. It will measure how much of the drug gets into the blood steam and how long the body takes to get rid of it. It will investigate anti-cancer activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3023414 | LY3023414 administered orally. |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-02-09
- Completion
- 2017-02-09
- First posted
- 2015-09-01
- Last updated
- 2018-07-24
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02536586. Inclusion in this directory is not an endorsement.